Skip to main content

Articles

Page 23 of 62

  1. Previous studies have suggested that high mean glucose levels and glycemic abnormalities such as glucose fluctuation and hypoglycemia accelerate the progression of atherosclerosis in patients with type 2 diabe...

    Authors: Satomi Wakasugi, Tomoya Mita, Naoto Katakami, Yosuke Okada, Hidenori Yoshii, Takeshi Osonoi, Nobuichi Kuribayashi, Yoshinobu Taneda, Yuichi Kojima, Masahiko Gosho, Iichiro Shimomura and Hirotaka Watada
    Citation: Cardiovascular Diabetology 2021 20:15
    Content type: Original investigation Published on:

  2. Emerging evidence suggests that sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with decreased risk of cardiovascular and renal event...

    Authors: Takayuki Yamada, Mako Wakabayashi, Abhinav Bhalla, Nitin Chopra, Hirotaka Miyashita, Takahisa Mikami, Hiroki Ueyama, Tomohiro Fujisaki, Yusuke Saigusa, Takahiro Yamaji, Kengo Azushima, Shingo Urate, Toru Suzuki, Eriko Abe, Hiromichi Wakui and Kouichi Tamura
    Citation: Cardiovascular Diabetology 2021 20:14
    Content type: Original investigation Published on:

  3. Diastolic dysfunction is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and is associated with overweight, glucose dysregulation and coronary artery disease (CAD). The GLP-1 receptor agonist...

    Authors: Preman Kumarathurai, Ahmad Sajadieh, Christian Anholm, Ole P. Kristiansen, Steen B. Haugaard and Olav W. Nielsen
    Citation: Cardiovascular Diabetology 2021 20:12
    Content type: Original investigation Published on:

  4. Patients with type 2 diabetes mellitus (T2DM) are susceptible to coexisted with chronic kidney disease (CKD), which may increase cardiovascular mortality in these patients. The present study aimed to verify wh...

    Authors: Yi Zhang, Jin Wang, Yan Ren, Wei-feng Yan, Li Jiang, Yuan Li and Zhi-gang Yang
    Citation: Cardiovascular Diabetology 2021 20:11
    Content type: Original investigation Published on:

  5. We investigated the association of insulin resistance (IR) with coronary plaque morphology and the risk of cardiovascular events in patients enrolled in the Providing Regional Observations to Study Predictors ...

    Authors: Serdar Farhan, Björn Redfors, Akiko Maehara, Thomas McAndrew, Ori Ben-Yehuda, Bernard De Bruyne, Roxana Mehran, Birgit Vogel, Gennaro Giustino, Patrick W. Serruys, Gary S. Mintz and Gregg W. Stone
    Citation: Cardiovascular Diabetology 2021 20:10
    Content type: Original investigation Published on:

  7. Risk stratification of cardiovascular events in patients with type 2 diabetes mellitus (T2DM) has not been established. Coronary artery calcium score (CACS) and non-alcoholic fatty liver disease (NAFLD) are in...

    Authors: Keishi Ichikawa, Toru Miyoshi, Kazuhiro Osawa, Takashi Miki, Hironobu Toda, Kentaro Ejiri, Masatoki Yoshida, Yusuke Nanba, Masashi Yoshida, Kazufumi Nakamura, Hiroshi Morita and Hiroshi Ito
    Citation: Cardiovascular Diabetology 2021 20:8
    Content type: Original investigation Published on:

  8. Sodium–glucose linked transporter type 2 (SGLT-2) inhibition has been shown to reduce cardiovascular mortality in heart failure independently of glycemic control and prevents the onset of atrial arrhythmias, a...

    Authors: David Bode, Lukas Semmler, Paulina Wakula, Niklas Hegemann, Uwe Primessnig, Nicola Beindorff, David Powell, Raphael Dahmen, Hartmut Ruetten, Christian Oeing, Alessio Alogna, Daniel Messroghli, Burkert M. Pieske, Frank R. Heinzel and Felix Hohendanner
    Citation: Cardiovascular Diabetology 2021 20:7
    Content type: Original investigation Published on:

  9. In the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial) treatment with the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin significantly reduced heart failure hospitaliz...

    Authors: Matthias Rau, Kirsten Thiele, Niels-Ulrik Korbinian Hartmann, Alexander Schuh, Ertunc Altiok, Julia Möllmann, András P. Keszei, Michael Böhm, Nikolaus Marx and Michael Lehrke
    Citation: Cardiovascular Diabetology 2021 20:6
    Content type: Original investigation Published on:

  10. Evidence is limited about the joint health effects of the Mediterranean lifestyle on cardiometabolic health and mortality. The aim of this study was to evaluate the association of the Mediterranean lifestyle w...

    Authors: Mercedes Sotos-Prieto, Rosario Ortolá, Miguel Ruiz-Canela, Esther Garcia-Esquinas, David Martínez-Gómez, Esther Lopez-Garcia, Miguel Ángel Martínez-González and Fernando Rodriguez-Artalejo
    Citation: Cardiovascular Diabetology 2021 20:5
    Content type: Original investigation Published on:

  11. Tofogliflozin, an SGLT2 inhibitor, is associated with favorable metabolic effects, including improved glycemic control and serum lipid profile and decreased body weight, visceral adipose tissue, and blood pres...

    Authors: Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Keiichi Torimoto, Yutaka Umayahara, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi…
    Citation: Cardiovascular Diabetology 2021 20:4
    Content type: Original investigation Published on:

  12. Individuals with diabetes and lower-limb complications are at high risk for cardiovascular and all-cause mortality, but uncertainties remain in terms of cancer-related death in this population. We investigated...

    Authors: Kamel Mohammedi, Stephen Harrap, Giuseppe Mancia, Michel Marre, Neil Poulter, John Chalmers and Mark Woodward
    Citation: Cardiovascular Diabetology 2021 20:3
    Content type: Original investigation Published on:

  13. The prevalence of cardiomyopathy is higher in diabetic patients than those without diabetes. Diabetic cardiomyopathy (DCM) is defined as a clinical condition of abnormal myocardial structure and performance in...

    Authors: Lin Wang, Yin Cai, Liguo Jian, Chi Wai Cheung, Liangqing Zhang and Zhengyuan Xia
    Citation: Cardiovascular Diabetology 2021 20:2
    Content type: Review Published on:

  14. Recent cardiovascular outcome trials have shown significant reductions in major cardiovascular (CV) events with glucagon-like peptide (GLP)-1 receptor agonists. Additionally, adjunctive surrogates for cardiova...

    Authors: Antonino Tuttolomondo, Anna Cirrincione, Alessandra Casuccio, Alessandro Del Cuore, Mario Daidone, Tiziana Di Chiara, Domenico Di Raimondo, Vittoriano Della Corte, Carlo Maida, Irene Simonetta, Stefania Scaglione and Antonio Pinto
    Citation: Cardiovascular Diabetology 2021 20:1
    Content type: Original investigation Published on:

  15. It has been suggested the COVID pandemic may have indirectly affected the treatment and outcome of STEMI patients, by avoidance or significant delays in contacting the emergency system. No data have been repor...

    Authors: Giuseppe De Luca, Miha Cercek, Lisette Okkels Jensen, Marija Vavlukis, Lucian Calmac, Tom Johnson, Gerard Roura i Ferrer, Vladimir Ganyukov, Wojtek Wojakowski, Clemens von Birgelen, Francesco Versaci, Jurrien Ten Berg, Mika Laine, Maurits Dirksen, Gianni Casella, Petr Kala…
    Citation: Cardiovascular Diabetology 2020 19:215
    Content type: Original investigation Published on:

  16. Type 2 diabetes (T2D) patients are at a greater risk of cardiovascular events due to aggravated atherosclerosis. Oxidized LDL (oxLDL) has been shown to be increased in T2D plaques and suggested to contribute t...

    Authors: Pratibha Singh, Isabel Goncalves, Christoffer Tengryd, Mihaela Nitulescu, Ana F. Persson, Fong To, Eva Bengtsson, Petr Volkov, Marju Orho-Melander, Jan Nilsson and Andreas Edsfeldt
    Citation: Cardiovascular Diabetology 2020 19:214
    Content type: Original investigation Published on:

    The Correction to this article has been published in Cardiovascular Diabetology 2021 20:61

  17. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Masatoki Yoshida, Kazufumi Nakamura, Toru Miyoshi, Masashi Yoshida, Megumi Kondo, Kaoru Akazawa, Tomonari Kimura, Hiroaki Ohtsuka, Yuko Ohno, Daiji Miura and Hiroshi Ito
    Citation: Cardiovascular Diabetology 2020 19:213
    Content type: Correction Published on:

    The original article was published in Cardiovascular Diabetology 2020 19:149

  18. Heart failure is a common and devastating complication of type 2 diabetes (T2D). Prompt recognition of heart failure may avert hospitalization, facilitate use of guideline-directed therapies, and impact choice...

    Authors: Suzanne V. Arnold, Philip G. Jones, Michael Beasley, Jeanine Cordova, Abhinav Goyal, Gregg C. Fonarow and Leo Seman
    Citation: Cardiovascular Diabetology 2020 19:212
    Content type: Original investigation Published on:

  19. The aim of this study was to investigate the association of visit-to-visit variability of hemoglobin A1c (HbA1c) and glycated albumin (GA) with the risk of lower extremity atherosclerotic disease (LEAD).

    Authors: Yun Shen, Dongjun Dai, Jingyi Lu, Yufei Wang, Wei Zhu, Yuqian Bao, Gang Hu and Jian Zhou
    Citation: Cardiovascular Diabetology 2020 19:211
    Content type: Original investigation Published on:

  20. Ischemic heart disease (IHD) without diabetes is considered an important challenge to human health and is associated with a poor prognosis, as well as a lack of health awareness. We prospectively investigated ...

    Authors: Byoungjin Park, Yong-Jae Lee, Hye Sun Lee and Dong-Hyuk Jung
    Citation: Cardiovascular Diabetology 2020 19:210
    Content type: Original investigation Published on:

  21. Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates cholesterol metabolism by targeting the low-density lipoprotein receptor. Recent studies have shown that circulating PCSK9 is associated with glu...

    Authors: Jie Shi, Weiwei Zhang, Yixin Niu, Ning Lin, Xiaoyong Li, Hongmei Zhang, Renming Hu, Guang Ning, Jiangao Fan, Li Qin, Qing Su and Zhen Yang
    Citation: Cardiovascular Diabetology 2020 19:209
    Content type: Original investigation Published on:

  22. We have previously reported that in patients with type 2 diabetes (T2D) consumption of a very low carbohydrate diet capable of inducing nutritional ketosis over 2 years (continuous care intervention, CCI) resu...

    Authors: Shaminie J. Athinarayanan, Sarah J. Hallberg, Amy L. McKenzie, Katharina Lechner, Sarah King, James P. McCarter, Jeff S. Volek, Stephen D. Phinney and Ronald M. Krauss
    Citation: Cardiovascular Diabetology 2020 19:208
    Content type: Original investigation Published on:

    The Correction to this article has been published in Cardiovascular Diabetology 2021 20:37

  23. Glucose oxidation is a major contributor to myocardial energy production and its contribution is orchestrated by insulin. While insulin can increase glucose oxidation indirectly by enhancing glucose uptake and...

    Authors: Qutuba G. Karwi, Cory S. Wagg, Tariq R. Altamimi, Golam M. Uddin, Kim L. Ho, Ahmed M. Darwesh, John M. Seubert and Gary D. Lopaschuk
    Citation: Cardiovascular Diabetology 2020 19:207
    Content type: Original investigation Published on:

  25. Information on the clinical characteristics and outcomes of hospitalized Covid-19 patients with or without diabetes mellitus (DM) is limited in the Arab region. This study aims to fill this gap.

    Authors: Abdullah M. Alguwaihes, Mohammed E. Al-Sofiani, Maram Megdad, Sakhar S. Albader, Mohammad H. Alsari, Ali Alelayan, Saad H. Alzahrani, Shaun Sabico, Nasser M. Al-Daghri and Anwar A. Jammah
    Citation: Cardiovascular Diabetology 2020 19:205
    Content type: Original investigation Published on:

  26. Diabetes is an increasingly important risk factor for ischemic stroke and worsens stroke prognosis. Yet a large proportion of stroke patients who are eventually diabetic are undiagnosed. Therefore, it is impor...

    Authors: Karl Matz, Jaakko Tuomilehto, Yvonne Teuschl, Alexandra Dachenhausen and Michael Brainin
    Citation: Cardiovascular Diabetology 2020 19:204
    Content type: Original investigation Published on:

  27. Early arterial healing after drug-eluting stent (DES) implantation may enable short dual-antiplatelet therapy (DAPT) strategy. The impact of diabetes mellitus (DM) on this healing has not been elucidated. We u...

    Authors: Takayuki Ishihara, Yohei Sotomi, Takuya Tsujimura, Osamu Iida, Tomoaki Kobayashi, Yuma Hamanaka, Takashi Omatsu, Yasushi Sakata, Yoshiharu Higuchi and Toshiaki Mano
    Citation: Cardiovascular Diabetology 2020 19:203
    Content type: Original investigation Published on:

  28. To evaluate the effects of cardiac resynchronization therapy (CRTd) in patients with type 2 diabetes mellitus (T2DM) optimized via automatic vs. echocardiography-guided approach.

    Authors: Celestino Sardu, Pasquale Paolisso, Valentino Ducceschi, Matteo Santamaria, Cosimo Sacra, Massimo Massetti, Antonio Ruocco and Raffaele Marfella
    Citation: Cardiovascular Diabetology 2020 19:202
    Content type: Original investigation Published on:

  29. Currently available treatments have only been partly successful in patients with severe hypertriglyceridemia, including those with high serum triglycerides above 1,000 mg/dL (11.3 mmol/L), who often suffer fro...

    Authors: Chie Iitake, Daisaku Masuda, Masahiro Koseki and Shizuya Yamashita
    Citation: Cardiovascular Diabetology 2020 19:201
    Content type: Original investigation Published on:

  30. Patients with type 2 diabetes (T2D) and metabolic syndrome (MetS) are at greater cardiovascular risk than those with T2D without MetS. In the current report we aim to study the characteristics, cardio-renal ou...

    Authors: João Pedro Ferreira, Subodh Verma, David Fitchett, Anne Pernille Ofstad, Sabine Lauer, Isabella Zwiener, Jyothis George, Christoph Wanner, Bernard Zinman and Silvio E. Inzucchi
    Citation: Cardiovascular Diabetology 2020 19:200
    Content type: Original investigation Published on:

  31. The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) double blind randomized trial demonstrated that weekly subcutaneous dulaglutide 1.5 mg, a glucagon like peptide-1 receptor agon...

    Authors: Gilles R. Dagenais, Lars Rydén, Lawrence A. Leiter, Mark Lakshmanan, Leanne Dyal, Jeffrey L. Probstfield, Charles Messan Atisso, Jonathan E. Shaw, Ignacio Conget, William C. Cushman, Patricio Lopez-Jaramillo, Fernando Lanas, Ernesto German Cordona Munoz, Valdis Pirags, Nana Pogosova, Jan Basile…
    Citation: Cardiovascular Diabetology 2020 19:199
    Content type: Original investigation Published on:

  32. Metformin has been shown to have various cardiovascular benefits beyond its antihyperglycemic effects, including a reduction in stroke, heart failure, myocardial infarction, cardiovascular death, and all-cause...

    Authors: Teerapat Nantsupawat, Wanwarang Wongcharoen, Siriporn C. Chattipakorn and Nipon Chattipakorn
    Citation: Cardiovascular Diabetology 2020 19:198
    Content type: Review Published on:

  33. The relationship between adipocyte fatty acid-binding protein (AFABP) and cardiac remodelling has been reported in cross-sectional studies, although with conflicting results. Type 2 diabetes mellitus (T2DM) is...

    Authors: Mei-Zhen Wu, Chi-Ho Lee, Yan Chen, Shuk-Yin Yu, Yu-Juan Yu, Qing-Wen Ren, Ho-Yi Carol Fong, Pui-Fai Wong, Hung-Fat Tse, Siu-Ling Karen Lam and Kai-Hang Yiu
    Citation: Cardiovascular Diabetology 2020 19:197
    Content type: Original investigation Published on:

  34. Approximately half of all patients with type 2 diabetes (T2D) develop a certain degree of renal impairment. In many of them, chronic kidney disease (CKD) progresses over time, eventually leading to end-stage k...

    Authors: Francesco Giorgino, Jiten Vora, Peter Fenici and Anna Solini
    Citation: Cardiovascular Diabetology 2020 19:196
    Content type: Review Published on:

  35. We aimed to investigate the association of metabolic syndrome (MetS) and its single components with cardiovascular risk and estimated their impact on the prematurity of occurrence of cardiovascular events usin...

    Authors: María J. Guembe, Cesar I. Fernandez-Lazaro, Carmen Sayon-Orea, Estefanía Toledo and Conchi Moreno-Iribas
    Citation: Cardiovascular Diabetology 2020 19:195
    Content type: Original investigation Published on:

  36. The prevalence of peripheral artery disease (PAD) is obviously increased in patients with diabetes. Existing evidence shows that cysteine-rich angiogenic inducer 61 (Cyr61), a 40-kD secreted protein, plays imp...

    Authors: Bin Feng, Guidong Xu, Kangyun Sun, Kaipeng Duan, Bimin Shi and Nannan Zhang
    Citation: Cardiovascular Diabetology 2020 19:194
    Content type: Original investigation Published on:

  37. Type 2 Diabetes Mellitus (T2DM) is a well-known comorbidity to COVID-19 and coagulopathies are a common accompaniment to both T2DM and COVID-19. In addition, patients with COVID-19 are known to develop micro-c...

    Authors: Etheresia Pretorius, Chantelle Venter, Gert Jacobus Laubscher, Petrus Johannes Lourens, Janami Steenkamp and Douglas B. Kell
    Citation: Cardiovascular Diabetology 2020 19:193
    Content type: Original investigation Published on:

  38. Type 2 diabetes mellitus (T2DM) is associated with an increased cardiovascular risk related at least in part to a more vulnerable plaque phenotype. However, patients with T2DM exhibit also an increased risk fo...

    Authors: Rosalia Dettori, Andrea Milzi, Kathrin Burgmaier, Mohammad Almalla, Martin Hellmich, Nikolaus Marx, Sebastian Reith and Mathias Burgmaier
    Citation: Cardiovascular Diabetology 2020 19:192
    Content type: Original investigation Published on:

  39. The “obesity paradox” has not been elucidated in the long-term outcomes of acute coronary syndrome (ACS). We investigated the association between obesity and cardiovascular (CV) outcomes in ACS patients with a...

    Authors: Se-Jun Park, Kyoung Hwa Ha and Dae Jung Kim
    Citation: Cardiovascular Diabetology 2020 19:191
    Content type: Original investigation Published on:

  40. The well-established benefit of Low-Dense-Lipoprotein-cholesterol (LDL-c) lowering treatments (LLTs) has led clinical guidelines to lower the cardiovascular prevention targets. Despite this, there is a surpris...

    Authors: Mario Luca Morieri, Angelo Avogaro and Gian Paolo Fadini
    Citation: Cardiovascular Diabetology 2020 19:190
    Content type: Original investigation Published on:

  41. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) has shown evidence of cardiovascular benefit in patients with type 2 diabetes mellitus (T2DM). Currently metformin is the guideline-recommended first-line tr...

    Authors: Tien-Hsing Chen, Yan-Rong Li, Shao-Wei Chen, Yu-Sheng Lin, Chi-Chin Sun, Dong-Yi Chen, Chun-Tai Mao, Michael Wu, Chih-Hsiang Chang, Pao-Hsien Chu and Victor Chien-Chia Wu
    Citation: Cardiovascular Diabetology 2020 19:189
    Content type: Original investigation Published on:

  42. Sodium glucose cotransporter 2 inhibitor (SGLT2i) reduces the risk of hard cardiovascular endpoints in type 2 diabetes mellitus (T2DM) patients with/without established cardiovascular diseases. Whether SGLT2i ...

    Authors: Ann Wan-Chin Ling, Cze-Ci Chan, Shao-Wei Chen, Yi-Wei Kao, Chien-Ying Huang, Yi-Hsin Chan and Pao-Hsien Chu
    Citation: Cardiovascular Diabetology 2020 19:188
    Content type: Original investigation Published on:

  43. Depression and cardiovascular disease (CVD) are among the most common causes of disability in high-income countries, depression being associated with a 30% increased risk of future CV events. Depression is twi...

    Authors: C. Macchi, C. Favero, A. Ceresa, L. Vigna, D. M. Conti, A. C. Pesatori, G. Racagni, A. Corsini, N. Ferri, C. R. Sirtori, M. Buoli, V. Bollati and M. Ruscica
    Citation: Cardiovascular Diabetology 2020 19:187
    Content type: Original investigation Published on:

  44. The association between alkaline phosphatase (ALP) and incident diabetes remains uncertain. Our study aimed to investigate the prospective relation of serum ALP with the risk of new-onset diabetes, and explore...

    Authors: Yuanyuan Zhang, Chun Zhou, Jianping Li, Yan Zhang, Di Xie, Min Liang, Binyan Wang, Yun Song, Xiaobin Wang, Yong Huo, Fan Fan Hou, Xiping Xu and Xianhui Qin
    Citation: Cardiovascular Diabetology 2020 19:186
    Content type: Original investigation Published on:

  45. The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed to herald a new era in the management of type 2 diabetes (T2D), especially for the many patients with T2D who are at ...

    Authors: Guntram Schernthaner, Naim Shehadeh, Alexander S. Ametov, Anna V. Bazarova, Fahim Ebrahimi, Peter Fasching, Andrej Janež, Péter Kempler, Ilze Konrāde, Nebojša M. Lalić, Boris Mankovsky, Emil Martinka, Dario Rahelić, Cristian Serafinceanu, Jan Škrha, Tsvetalina Tankova…
    Citation: Cardiovascular Diabetology 2020 19:185
    Content type: Commentary Published on:

  46. Cardiovascular magnetic resonance imaging (CMR) have described localised non-ischemic late gadolinium enhancement (LGE) lesions of prognostic importance in various non-ischemic cardiomyopathies. Ischemic LGE l...

    Authors: Annemie Stege Bojer, Martin Heyn Sørensen, Niels Vejlstrup, Jens P. Goetze, Peter Gæde and Per Lav Madsen
    Citation: Cardiovascular Diabetology 2020 19:184
    Content type: Original investigation Published on:

  47. High-sensitivity C-reactive protein (hs-CRP) elevation frequently occurs in acute myocardial infarction (AMI) and is associated with adverse outcomes. Since diabetes mellitus (DM) is characterized by an underl...

    Authors: Claudia Lucci, Nicola Cosentino, Stefano Genovese, Jeness Campodonico, Valentina Milazzo, Monica De Metrio, Maurizio Rondinelli, Daniela Riggio, Maria Luisa Biondi, Mara Rubino, Katia Celentano, Alice Bonomi, Nicolò Capra, Fabrizio Veglia, Piergiuseppe Agostoni, Antonio L. Bartorelli…
    Citation: Cardiovascular Diabetology 2020 19:183
    Content type: Original investigation Published on:

  48. The global epidemic of diabetes mellitus continues to grow and affects developed and developing countries alike. Intensive glycemic control is thought to modify the risks for vascular complications, hence the ...

    Authors: Wei Ling, Yi Huang, Yan-Mei Huang, Rong-Rong Fan, Yi Sui and Hai-Lu Zhao
    Citation: Cardiovascular Diabetology 2020 19:182
    Content type: Original investigation Published on:

  49. Little is known about age-specific target blood pressure (BP) in hypertensive patients with diabetes mellitus (DM). The aim of this study was to determine the BP level at the lowest cardiovascular risk of hype...

    Authors: Hack-Lyoung Kim, Hyue Mee Kim, Chang Hee Kwon, Jeong-Hun Shin, Mi-Hyang Jung, Chan Joo Lee, Dae-Hee Kim, Woo-Hyeun Kim, Si-Hyuck Kang, Ju-Hee Lee, In Jeong Cho, Iksung Cho, Jun Hyeok Lee, Dae Ryong Kang, Hae-Young Lee, Wook-Jin Chung…
    Citation: Cardiovascular Diabetology 2020 19:181
    Content type: Original investigation Published on:

  50. Mid-regional pro-atrial natriuretic peptide (MR-proANP) is a useful biomarker in outpatients with type 2 diabetes (T2D) to diagnose heart failure (HF). Elevated B-type natriuretic peptides are included in the ...

    Authors: Jesper Jensen, Morten Schou, Caroline Kistorp, Jens Faber, Tine W. Hansen, Magnus T. Jensen, Henrik U. Andersen, Peter Rossing, Tina Vilsbøll and Peter G. Jørgensen
    Citation: Cardiovascular Diabetology 2020 19:180
    Content type: Original investigation Published on:
journal logo

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Submit manuscript

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 8.5
    5-year Journal Impact Factor: 8.9
    Source Normalized Impact per Paper (SNIP): 1.855
    SCImago Journal Rank (SJR): 2.621

    Speed 2023
    Submission to first editorial decision (median days): 2
    Submission to acceptance (median days): 56

    Usage 2023
    Downloads: 2,523,778
    Altmetric mentions: 3,115

Cardiovascular Diabetology

ISSN: 1475-2840